<DOC>
	<DOCNO>NCT00477581</DOCNO>
	<brief_summary>This purpose study compare effect exenatide sitagliptin 2-hour postprandial glucose subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Compare Effects Exenatide Sitagliptin Postprandial Glucose Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Treatment metformin least 2 month Has HbA1c 7.0 % 11.0 % , inclusive , screen Body mass index ( BMI ) 25 kg/m^2 45 kg/m^2 , inclusive List medication allow patient stable treatment least 2 month : Hormone replacement therapy ( female subject ) Oral contraceptive ( female subject ) Antihypertensive agent Lipidlowering agent Thyroid replacement therapy Exclusion Criteria Has treat exenatide ( BYETTA速 ) DPP4 inhibitor prior screen Received study medication participate type clinical trial within 30 day prior screen Has donate blood within 60 day screen visit planning donate blood study Treated follow medication : Sulfonylurea Thiazolidinedione within 3 month screen ; Alphaglucosidase inhibitor , meglitinide , nateglinide , pramlintide ( SYMLIN速 ) within 30 day screen ; Insulin within 2 week prior screen insulin longer 1 week within 6 month screen ; Drugs directly affect gastrointestinal motility , include limited , anticholinergic , macrolide antibiotic , dopamine antagonist , opioids , Reglan速 ( metoclopramide ) ; Systemic corticosteroid oral , intravenous , intramuscular route ; potent , inhale , intrapulmonary ( include ADVAIR速 ) steroid know high rate systemic absorption ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>